1. Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer.
- Author
-
Plichta KA, Graves SA, and Buatti JM
- Subjects
- Antigens, Surface isolation & purification, Antigens, Surface therapeutic use, Glutamate Carboxypeptidase II isolation & purification, Glutamate Carboxypeptidase II therapeutic use, Humans, Male, Neoplasm Metastasis, Precision Medicine, Prostate diagnostic imaging, Prostate pathology, Prostatic Neoplasms diagnostic imaging, Prostatic Neoplasms genetics, Radiopharmaceuticals therapeutic use, Theranostic Nanomedicine trends, Antigens, Surface genetics, Glutamate Carboxypeptidase II genetics, Prostate drug effects, Prostatic Neoplasms diagnosis, Prostatic Neoplasms therapy
- Abstract
Theranostics, a combination of therapy and diagnostics, is a field of personalized medicine involving the use of the same or similar radiopharmaceutical agents for the diagnosis and treatment of patients. Prostate-specific membrane antigen (PSMA) is a promising theranostic target for the treatment of prostate cancers. Diagnostic PSMA radiopharmaceuticals are currently used for staging and diagnosis of prostate cancers, and imaging can predict response to therapeutic PSMA radiopharmaceuticals. While mainly used in the setting of metastatic, castrate-resistant disease, clinical trials are investigating the use of PSMA-based therapy at earlier stages, including in hormone-sensitive or hormone-naïve prostate cancers, and in oligometastatic prostate cancers. This review explores the use of PSMA as a theranostic target and investigates the potential use of PSMA in earlier stage disease, including hormone-sensitive metastatic prostate cancer, and oligometastatic prostate cancer.
- Published
- 2021
- Full Text
- View/download PDF